Durata Therapeutics, Inc. Announces Five Abstracts Concerning Dalbavancin and Management of abSSTI at ICAAC 2012
8/29/2012 10:11:11 AM
MORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced that data from multiple studies of its investigational drug dalbavancin and of the outpatient management of acute bacterial skin and soft tissue infection (abSSTI) will be presented in five posters during the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The conference will be held in San Francisco, CA from September 9-12, 2012.
comments powered by